Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Diabetologia
Erschienen in: Diabetologia 12/2005

01.12.2005 | Review

Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies

verfasst von: T. Cukierman, H. C. Gerstein, J. D. Williamson

Erschienen in: Diabetologia | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We systematically reviewed and summarised prospective data relating diabetes status to changes in cognitive function over time.

Methods

Published reports of longitudinal studies that described assessment of cognitive function in people with diabetes were sought. Studies were included if they assessed cognitive function in participants with diabetes at the beginning and at follow-up. Studies were excluded if they had (1) a follow-up period of less than 1 year, (2) a rate of loss to follow-up in excess of 30%, or (3) described selected subgroups. Change in cognitive function was recorded as either the mean change in score and/or the proportion of individuals developing various degrees of change in cognitive function. A pooled estimate was calculated for the latter.

Results

Of 1,165 abstracts and titles initially identified, 25 articles met the inclusion and exclusion criteria. Individuals with diabetes had a 1.2- to 1.5-fold greater change over time in measures of cognitive function than those without diabetes. When assessed by the Mini-Mental State Exam and the Digit Symbol Span tests, a diagnosis of diabetes increased the odds of cognitive decline 1.2-fold (95% CI 1.05–1.4) and 1.7-fold (95% CI 1.3–2.3), respectively . The odds of future dementia increased 1.6-fold (95% CI 1.4–1.8).

Conclusions/interpretation

Compared to people without diabetes, people with diabetes have a greater rate of decline in cognitive function and a greater risk of cognitive decline. Cognitive dysfunction should therefore be added to the list of chronic complications of diabetes.
Literatur
1.
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRef
2.
Thomas VS, Darvesh S, MacKnight C, Rockwood K (2001) Estimating the prevalence of dementia in elderly people: a comparison of the Canadian Study of Health and Aging and National Population Health Survey approaches. Int Psychogeriatr 13 (Suppl 1):169–175CrossRefPubMed
3.
Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490:169–175CrossRefPubMed
4.
5.
Lobo A, Launer LJ, Fratiglioni L et al (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54(Suppl 5):S4–S9PubMed
6.
Stewart R, Liolitsa D (1999) Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16:93–112CrossRefPubMed
7.
Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26:1044–1080CrossRefPubMed
8.
Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH (2002) Ageing and diabetes: implications for brain function. Eur J Pharmacol 441:1–14CrossRefPubMed
9.
Strachan MW, Frier BM, Deary IJ (2003) Type 2 diabetes and cognitive impairment. Diabet Med 20:1–2CrossRefPubMed
10.
Strachan MW, Deary IJ, Ewing FM, Frier BM (1997) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20:438–445PubMedCrossRef
11.
Strachan MW, Frier BM, Deary IJ (1997) Cognitive assessment in diabetes: the need for consensus. Diabet Med 14:421–422CrossRefPubMed
12.
Horwitz RI, Feinstein AR (1979) Methodologic standards and contradictory results in case-control research. Am J Med 66:556–564CrossRefPubMed
13.
Morris MC, Evans DA, Hebert LE, Bienias JL (1999) Methodological issues in the study of cognitive decline. Am J Epidemiol 149:789–793PubMed
14.
Colsher PL, Wallace RB (1991) Epidemiologic considerations in studies of cognitive function in the elderly: methodology and nondementing acquired dysfunction. Epidemiol Rev 13:1–27PubMed
15.
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
16.
Teng EL, Chui HC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatr 48:314–318
17.
Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935PubMed
18.
Brayne C, Spiegelhalter DJ, Dufouil C et al (1999) Estimating the true extent of cognitive decline in the old. J Am Geriatr Soc 47:1283–1288PubMed
19.
Wechsler D (1981) The Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation, New York
20.
Laird NM, Mosteller F (1990) Some statistical methods for combining experimental results. Int J Technol Assess Health Care 6:5–30PubMedCrossRef
21.
Desmond DW, Moroney JT, Sano M, Stern Y (1996) Recovery of cognitive function after stroke. Stroke 27:1798–1803PubMed
22.
Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C (2000) Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke 31:2431–2436PubMed
23.
Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D (2001) Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 57:1216–1222PubMed
24.
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1996) Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 27:2230–2235PubMed
25.
Hewer W, Mussell M, Rist F, Kulzer B, Bergis K (2003) Short-term effects of improved glycemic control on cognitive function in patients with type 2 diabetes. Gerontology 49:86–92CrossRefPubMed
26.
Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48:M117–M121PubMed
27.
Korten AE, Henderson AS, Christensen H et al (1997) A prospective study of cognitive function in the elderly. Psychol Med 27:919–930CrossRefPubMed
28.
de Moraes SA, Szklo M, Tilling K, Sato R, Knopman D (2003) Cognitive functioning as a predictor of ischemic stroke incidence. Epidemiology 14:673–679PubMedCrossRef
29.
Feskens EJ, Havekes LM, Kalmijn S, de KP, Launer LJ, Kromhout D (1994) Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ 309:1202–1206PubMed
30.
Gregg EW, Mangione CM, Cauley JA et al (2002) Diabetes and incidence of functional disability in older women. Diabetes Care 25:61–67PubMedCrossRef
31.
Grodstein F, Chen J, Pollen DA et al (2000) Postmenopausal hormone therapy and cognitive function in healthy older women. J Am Geriatr Soc 48:746–752PubMed
32.
Hu FB, Stampfer MJ, Solomon CG et al (2001) The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161:1717–1723CrossRefPubMed
33.
Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM (1999) Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 150:283–289PubMed
34.
Launer LJ, Feskens EJ, Kalmijn S, Kromhout D (1996) Smoking, drinking, and thinking. The Zutphen Elderly Study. Am J Epidemiol 143:219–227PubMed
35.
Launer LJ, Ross GW, Petrovitch H et al (2000) Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 21:49–55CrossRefPubMed
36.
Lui LY, Stone K, Cauley JA, Hillier T, Yaffe K (2003) Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc 51:38–43CrossRefPubMed
37.
Ott A, Stolk RP, Hofman A, van HF, Grobbee DE, Breteler MM (1996) Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39:1392–1397CrossRefPubMed
38.
Szklo M, Cerhan J, Diez-Roux AV et al (1996) Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 144:1048–1057PubMed
39.
Wilson RS, Beckett LA, Bienias JL, Evans DA, Bennett DA (2003) Terminal decline in cognitive function. Neurology 60:1782–1787PubMedCrossRef
40.
Yaffe K, Cauley J, Sands L, Browner W (1997) Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 54:1110–1114PubMed
41.
Yaffe K, Grady D, Pressman A, Cummings S (1998) Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 46:816–821PubMed
42.
Yaffe K, Browner W, Cauley J, Launer L, Harris T (1999) Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 47:1176–1182PubMed
43.
Yaffe K, Barnes D, Nevitt M, Lui LY, Covinsky K (2001) A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch Intern Med161:1703–1708CrossRefPubMed
44.
de Moraes SA, Szklo M, Knopman D, Park E (2001) Prospective assessment of estrogen replacement therapy and cognitive functioning: atherosclerosis risk in communities study. Am J Epidemiol 154:733–739CrossRefPubMed
45.
Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A (1999) Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 53:1948–1952PubMed
46.
Logroscino G, Kang JH, Grodstein F (2004) Prospective study of type 2 diabetes and cognitive decline in women aged 70–81 years. BMJ 328:548CrossRefPubMed
47.
Nguyen HT, Black SA, Ray LA, Espino DV, Markides KS (2002) Predictors of decline in MMSE scores among older Mexican Americans. J Gerontol A Biol Sci Med Sci 57:M181–M185PubMed
48.
Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH (2003) Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 56:686–693CrossRefPubMed
49.
Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH (2003) Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol 13:369–376CrossRefPubMed
50.
Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ (2003) Prevalence of dementia in older Ltinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriat Soc 51:169–177CrossRefPubMed
51.
Fontbonne A, Berr C, Ducimetiere P, Alperovitch A (2001) Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 24:366–370PubMedCrossRef
52.
Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L (1999) The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282:40–46CrossRefPubMed
53.
Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO (1993) Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 3:358–366PubMedCrossRef
54.
Gregg EW, Yaffe K, Cauley JA et al (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160:174–180CrossRefPubMed
55.
Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE (2004) Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 59:268–274PubMed
56.
Ott A, Stolk RP, van HF, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53:1937–1942PubMed
57.
Yoshitake T, Kiyohara Y, Kato I et al (1995) Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 45:1161–1168PubMed
58.
Leibson CL, Rocca WA, Hanson VA et al (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308PubMed
59.
Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multi-ethnic cohort. Am J Epidemiol 154:635–641CrossRefPubMed
60.
Cerhan JR, Folsom AR, Mortimer JA et al (1998) Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology 44:95–105CrossRefPubMed
61.
Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42–48PubMed
62.
Stewart R, Prince M, Mann A (2003) Age, vascular risk, and cognitive decline in an older, British, African-Caribbean population. J Am Geriat Soc 51:1547–1553CrossRefPubMed
63.
Robertson-Tchabo EA, Arenberg D, Tobin JD, Plotz JB (1986) A longitudinal study of cognitive performance in noninsulin dependent (type II) diabetic men. Exp Gerontol 21:459–467CrossRefPubMed
64.
MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14:77–83CrossRefPubMed
65.
Hassing LB, Hofer SM, Nilsson SE et al (2004) Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 33:355–361CrossRefPubMed
66.
Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661–666CrossRefPubMed
67.
Peila R, Rodriguez BL, Launer LJ, Honolulu–Asia AS (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu–Asia Aging Study. Diabetes 51:1256–1262PubMedCrossRef
68.
Tervo S, Kivipelto M, Hanninen T et al (2004) Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 17:196–203CrossRefPubMed
69.
Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K (2004) Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 164:1327–1333CrossRefPubMed
70.
Yaffe K, Blackwell T, Kanaya AM, Davidowitz BA, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658–663PubMed
71.
Elias PK, Elias MF, D'Agostino RB et al (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20:1388–1395PubMedCrossRef
72.
Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G (2003) Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriat Soc 51:410–414CrossRefPubMed
73.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24:1069–1078PubMedCrossRef
74.
Swainson R, Hodges JR, Galton CJ et al (2001) Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord 12:265–280CrossRefPubMed
75.
Comijs HC, van TT, Geerlings SW et al (2004) Do severity and duration of depressive symptoms predict cognitive decline in older persons? Results of the Longitudinal Aging Study Amsterdam. Aging Clin Exp Res 16:226–232PubMed
76.
Paterniti S, Verdier-Taillefer MH, Dufouil C, Alperovitch A (2002) Depressive symptoms and cognitive decline in elderly people. Longitudinal study. Br J Psychiatr 181:406–410CrossRef
77.
Jorm AF (2000) Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 46:219–227CrossRefPubMed
78.
Reichard P, Pihl M (1994) Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm diabetes intervention study. Diabetes 43:313–317PubMedCrossRef
79.
Horie K, Miyata T, Yasuda T et al (1997) Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun 236:327–332CrossRefPubMed
80.
Vlassara H, Bucala R, Striker L (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138–151PubMed
81.
82.
Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriat Soc 53:695–699CrossRefPubMed
Metadaten
Titel
Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies
verfasst von
T. Cukierman
H. C. Gerstein
J. D. Williamson
Publikationsdatum
01.12.2005
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 12/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0023-4

Weitere Artikel der Ausgabe 12/2005

Diabetologia 12/2005 Zur Ausgabe

Reseach Letter

Leptin : adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes : relationship of the index to carotid intima–media thickness

Editorial

Spring harvest? Reflections on the rise of type 1 diabetes

Article Paper

A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study

EASD News Section

G.B. Morgagni Prizes 2006

Short Communication

Selective loss of glucose-induced amplification of insulin secretion in mouse pancreatic islets pretreated with sulfonylurea in the absence of fuels

Article

Visual fields correlate better than visual acuity to severity of diabetic retinopathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise